Access Pharma Provides an Update on ProLindac Development [View article]
Mike, Isn't Prolindac gong to compete with PARD's pltimum drug which has a similar safety profile and is further along in development. What are the advantages of Prolindac over PARD's platinum drug?
Great work, Mike! Thanks for the detailed and EARLY reporting on this stock. I bought a few months ago after reading some of your earlier reports and have made a nice killing. If Mugard works as well as recent company reports, ACCP is still very undervalued.
Access Pharma: MuGard, Pipeline Make for Appealing Acquisition Possibilities [View article]
Interview: Access Pharma CEO Provides Prospects Update [View article]
Access Pharma Provides an Update on ProLindac Development [View article]
Access Pharma: Upcoming Milestones [View article]